Historique
Article de Périodique
Cannabinoids in bipolar affective disorder: a review and discussion of their therapeutic potential (2005)
(Les cannabiboïdes dans le trouble affectif bipolaire : une revue de la littérature et discussion de leur potentiel thérapeutique)
Auteur(s) :
ASHTON, C. H. ;
MOORE, P. B. ;
GALLAGHER, P. ;
YOUNG, A. H.
Année
2005
Page(s) :
293-300
Sous-type de document :
Revue de la littérature / Literature review
Langue(s) :
Anglais
Refs biblio. :
105
Domaine :
Drogues illicites / Illicit drugs
Discipline :
PSY (Psychopathologie / Psychopathology)
Thésaurus mots-clés
MECANISME D'ACTION
;
TROUBLE BIPOLAIRE
;
PSYCHOSE MANIACO-DEPRESSIVE
;
CANNABINOIDES
;
CANNABIS
;
TETRAHYDROCANNABINOL
;
USAGE THERAPEUTIQUE
;
DEPRESSION
;
PHARMACOLOGIE
Résumé :
Bipolar affective disorder is often poorly controlled by prescribed drugs. Cannabis use is common in patients with this disorder and anecdotal reports suggest that some patients take it to alleviate symptoms of both mania and depression. We undertook a literature review of cannabis use by patients with bipolar disorder and of the neuropharmacological properties of cannabinoids suggesting possible therapeutic effects in this condition. No systematic studies of cannabinoids in bipolar disorder were found to exist, although some patients claim that cannabis relieves symptoms of mania and/or depression. The cannabinoids Delta(9)-tetrahydrocannabinol (THC) and cannabidiol (CBD) may exert sedative, hypnotic, anxiolytic, antidepressant, antipsychotic and anticonvulsant effects. Pure synthetic cannabinoids, such as dronabinol and nabilone and specific plant extracts containing THC, CBD, or a mixture of the two in known concentrations, are available and can be delivered sublingually. Controlled trials of these cannabinoids as adjunctive medication in bipolar disorder are now indicated.
Affiliation :
Department of Psychiatry, University of Newcastle upon Tyne, Royal Victoria Infirmary, Newcastle upon Tyne, UK
Cote :
A02836